Pioglitazone and cancer: Angel or demon?

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4913-4929

  Kostapanos, Michael S ^a,b   Elisaf, Moses S ^b   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Bladder; Cancer; Pioglitazone; Safety; Type 2 diabetes

Indexed keywords

ANGIOGENIC FACTOR; CYCLIN D1; CYCLOOXYGENASE 2; EXENDIN 4; FATTY ACID BINDING PROTEIN; GELATINASE A; GELATINASE B; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; LIRAGLUTIDE; MATRILYSIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROSTAGLANDIN E2; PROTEIN P53; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL; TROGLITAZONE;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BLADDER CARCINOGENESIS; BODY MASS; BREAST CANCER; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENVIRONMENTAL FACTOR; ESOPHAGUS CANCER; FOLLOW UP; G1 PHASE CELL CYCLE CHECKPOINT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; META ANALYSIS (TOPIC); METASTASIS POTENTIAL; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OBESITY; PANCREAS CANCER; PLACEBO EFFECT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ADENOCARCINOMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR VOLUME; UTERUS CANCER;

ANIMALS; CARCINOGENS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; PPAR GAMMA; RISK; THIAZOLIDINEDIONES;

EID: 84881339060     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990294     Document Type: Article

References (245)

1. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-8.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
3. Centers for Disease Control and prevention. Available at: http://www.cdc.gov/chronicdisease/resources/publications/AAG/dd t.htm.
4. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-41.
5. Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to cancer? Diabetes Metab J 2011; 35: 193-8.
6. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754-64.
7. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-23.
8. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008; 9: 1087-108.
9. Leiter LA. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. Diabet Med 2005; 22: 963-72.
10. Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007; 76: 163-76.
11. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010; 70: 1945-61.
12. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009; 8: 15-32.
13. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003; 98: 175-9.
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
15. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-95.
16. Division of Metabolism and Endocrine Products and Offi ce of Surveillance and Epidemiology, US Food and Drug Administration. FDA Briefing Document: joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. July 30, 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf.
17. The U.S. Food and Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021071 s040lbl.pdf.
18. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000268/WC500029109.pdf.
19. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-43.
20. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-73.
21. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-81.
22. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
23. Tseng CH. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? J Formos Med Assoc 2012; 111: 123-31.
24. Barbalat Y, Dombrovskiy VY, Weiss RE. Association Between Pioglitazone and Urothelial Bladder Cancer. Urology 2012; 80: 1-4.
25. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-85.
26. Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs 2010; 19: 913-7.
27. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328-36.
28. Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc 2008; 67: 128-45.
29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
30. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
31. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
32. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995; 18: 1113-23.
33. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011; 54: 25-31.
34. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
35. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-35.
36. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-8.
37. Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46: 279-84.
38. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; 23: 479-84.
39. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-50.
40. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-44.
41. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-708.
42. Gough SC, Belda-Iniesta C, Poole C, et al. Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK. Adv Ther 2011; 28 Suppl 5: 1-18.
43. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-61.
44. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-5.
45. Bo S, Ciccone G, Rosato R, et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 2011.
46. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010; 53: 1838-45.
47. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-6.
48. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27 Suppl 3: 57-64.
49. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-7.
50. The U.S. Food and Drug Administration. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAl ertsforHumanMedicalProducts/ucm258826.htm.
51. Wan Z, Shi W, Shao B, et al. Peroxisome proliferator-activated receptor gamma agonist pioglitazone inhibits beta-cateninmediated glioma cell growth and invasion. Mol Cell Biochem 2011; 349: 1-10.
52. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-81.
53. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007; 5: 17.
54. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008; 31: 1455-60.
55. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22.
56. The U.S. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm.
57. The U.S. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm.
58. European Medicines Agency. Available at: www.ema.eu/docs/eu_GB/document_library/Press_release/2011/07/WC500109176.pdf.
59. AFDSSDPD. Available at: http://www.afssaps.fr/Infos-desecurite/Communiques-Points-presse/Suspension-de-l-utilisationdes-medicaments-contenant-de-la-pioglitazone-Actos-RCompetact-R-Communique.
60. BFARM http://www.bfarm.de/EN/vigilance/riskinfo/2011/rhbpioglitazon2. html;jsessionid=531EA537F7AB715D533CE467CA4 C2628.1_cid103.
61. Ferrara A, Lewis JD, Quesenberry CP Jr., et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34: 923-9.
62. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferatoractivated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 2009; 8: 6-15.
63. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003; 104: 597-602.
64. Guan YF, Zhang YH, Breyer RM, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330-9.
65. Celis JE, Ostergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996; 56: 4782-90.
66. Possati L, Rocchetti R, Talevi S, et al. The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression. Gen Pharmacol 2000; 35: 269-75.
67. Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005; 23: 5746-56.
68. Huang JW, Shiau CW, Yang YT, et al. Peroxisome proliferatoractivated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005; 67: 1342-8.
69. Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010; 113: 349-57.
70. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005; 87: 322-7.
71. Tannehill-Gregg SH, Sanderson TP, Minnema D, et al. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci 2007; 98: 258-70.
72. Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006; 34: 903-20.
73. Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in nonneoplastic and neoplastic human urothelial cells. Am J Pathol 2001; 159: 591-7.
74. Jeremy JY, Tsang V, Mikhailidis DP, et al. Eicosanoid synthesis by human urinary bladder mucosa: pathological implications. Br J Urol 1987; 59: 36-9.
75. Mikhailidis DP, Jeremy JY, Dandona P. Urinary bladder prostanoids--their synthesis, function and possible role in the pathogenesis and treatment of disease. J Urol 1987; 137: 577-82.
76. Hazra S, Batra RK, Tai HH, et al. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007; 71: 1715-20.
77. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a populationbased cohort study. Diabetologia 2012; 55: 1953-62.
78. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34: 1369-71.
79. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-80.
80. Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: A propensity score matched cohort study. Br J Clin Pharmacol 2012; 75: 254-9.
81. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737-45.
82. Colin P, Koenig P, Ouzzane A, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009; 104: 1436-40.
83. Reulen RC, Kellen E, Buntinx F, et al. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl 2008: 64-78.
84. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54: 2009-15.
85. Reddy RC, Srirangam A, Reddy K, et al. Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 2008; 10: 597-603.
86. Nemenoff RA, Weiser-Evans M, Winn RA. Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptorgamma Ligands in Lung Cancer. PPAR Res 2008; 2008: 156875.
87. Sasaki H, Tanahashi M, Yukiue H, et al. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 2002; 36: 71-6.
88. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23: 100-8.
89. Keshamouni VG, Arenberg DA, Reddy RC, et al. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 2005; 7: 294-301.
90. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgammaindependent signal pathways. Mol Cancer Ther 2006; 5: 430-7.
91. Satoh T, Toyoda M, Hoshino H, et al. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002; 21: 2171-80.
92. Bren-Mattison Y, Van Putten V, Chan D, et al. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005; 24: 1412-22.
93. Kusakabe M, Watanabe K, Emoto N, et al. Impact of DNA demethylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists. Biochem Biophys Res Commun 2009; 390: 1283-7.
94. Fu H, Zhang J, Pan J, et al. Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. Mol Carcinog 2011; 50: 913-21.
95. Wang Y, James M, Wen W, et al. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther 2010; 9: 3074-82.
96. Li MY, Yuan H, Ma LT, et al. Roles of peroxisome proliferatoractivated receptor-alpha and-gamma in the development of nonsmall cell lung cancer. Am J Respir Cell Mol Biol 2010; 43: 674-83.
97. Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005; 4: 1349-57.
98. Ihle NT, Lemos R, Schwartz D, et al. Peroxisome proliferatoractivated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 2009; 8: 94-100.
99. Fenner MH, Elstner E. Peroxisome proliferator-activated receptorgamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 2005; 14: 557-68.
100. Park BH, Lee SB, Stolz DB, et al. Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. J Biol Chem 2011; 286: 20087-99.
101. Rashid-Kolvear F, Taboski MA, Nguyen J, et al. Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer 2010; 10: 390.
102. Yu HN, Lee YR, Noh EM, et al. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand. Cell Biol Int 2008; 32: 906-12.
103. Bonofiglio D, Cione E, Qi H, et al. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol 2009; 175: 1270-80.
104. Kim KY, Kim SS, Cheon HG. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol 2006; 72: 530-40.
105. Chbicheb S, Yao X, Rodeau JL, et al. EGR1 expression: a calcium and ERK1/2 mediated PPARgamma-independent event involved in the antiproliferative effect of 15-deoxy-Delta12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells. Biochem Pharmacol 2011; 81: 1087-97.
106. Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 2009; 8: 253-84.
107. Moon HS, Guo DD, Lee HG, et al. Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARgamma and inhibition of ERK 1/2. Cancer Sci 2010; 101: 396-402.
108. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
109. Ehrmann J, Jr., Vavrusova N, Collan Y, Kolar Z. Peroxisome proliferator-activated receptors (PPARs) in health and disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002; 146: 11-4.
110. Lu M, Kwan T, Yu C, et al. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005; 280: 6742-51.
111. Elstner E, Williamson EA, Zang C, et al. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74: 155-65.
112. Panigrahy D, Singer S, Shen LQ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110: 923-32.
113. Huang H, Campbell SC, Bedford DF, et al. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2004; 2: 541-50.
114. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000; 60: 1604-8.
115. Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 5671-3.
116. Yin Y, Russell RG, Dettin LE, et al. Peroxisome proliferatoractivated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 2005; 65: 3950-7.
117. Tikoo K, Kumar P, Gupta J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 2009; 9: 107.
118. Yee LD, Young DC, Rosol TJ, et al. Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. J Nutr 2005; 135: 983-8.
119. Burstein HJ, Demetri GD, Mueller E, et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79: 391-7.
120. Yee LD, Williams N, Wen P, et al. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 2007; 13: 246-52.
121. Liu H, Zang C, Fenner MH, et al. PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 2003; 79: 63-74.
122. Bojkova B, Garajova M, Kajo K, et al. Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev 2010; 19: 379-84.
123. Su W, Bush CR, Necela BM, et al. Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. Physiol Genomics 2007; 30: 342-53.
124. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-52.
125. Yoshizumi T, Ohta T, Ninomiya I, et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 2004; 25: 631-9.
126. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002; 99: 13771-6.
127. Kitamura S, Miyazaki Y, Hiraoka S, et al. PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. Int J Cancer 2001; 94: 335-42.
128. Chen A, Xu J. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005; 288: G447-56.
129. Chen F, Harrison LE. Ciglitazone-induced cellular antiproliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell Signal 2005; 17: 809-16.
130. Theocharis S, Margeli A, Vielh P, Kouraklis G. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 2004; 30: 545-54.
131. Chen F, Kim E, Wang CC, Harrison LE. Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway. Cell Signal 2005; 17: 1572-7.
132. Chen GG, Xu H, Lee JF, et al. 15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. Int J Cancer 2003; 107: 837-43.
133. Chen GG, Lee JF, Wang SH, et al. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 2002; 70: 2631-46.
134. Lee CJ, Han JS, Seo CY, et al. Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells. Apoptosis 2006; 11: 401-11.
135. Yasui Y, Hosokawa M, Sahara T, et al. Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 113-9.
136. Shimada T, Kojima K, Yoshiura K, et al. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-64.
137. Dai Y, Wang WH. Peroxisome proliferator-activated receptor gamma and colorectal cancer. World J Gastrointest Oncol 2010; 2: 159-64.
138. Cesario RM, Stone J, Yen WC, et al. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett 2006; 240: 225-33.
139. Shimizu M, Moriwaki H. Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment. PPAR Res 2008; 2008: 181047.
140. Sunami E, Tsuno NH, Kitayama J, et al. Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone. Surg Today 2002; 32: 343-50.
141. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61: 2424-8.
142. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-61.
143. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-7.
144. Kulke MH, Demetri GD, Sharpless NE, et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8: 395-9.
145. Papi A, Rocchi P, Ferreri AM, Orlandi M. RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Lett 2010; 297: 65-74.
146. Takano S, Kubota T, Nishibori H, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 2008; 28: 3593-9.
147. Shen D, Deng C, Zhang M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J 2007; 83: 414-9.
148. Choi IK, Kim YH, Kim JS, Seo JH. PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. Invest New Drugs 2008; 26: 283-8.
149. Mutoh M, Niho N, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol Chem 2006; 387: 381-5.
150. Niho N, Takahashi M, Kitamura T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003; 63: 6090-5.
151. Niho N, Takahashi M, Shoji Y, et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci 2003; 94: 960-4.
152. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferatoractivated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003; 124: 361-7.
153. Takahashi H, Hosono K, Uchiyama T, et al. PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. PPAR Res 2010; 2010.
154. Wu GJ, Sinclair CS, Paape J, et al. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res 2000; 60: 5371-5.
155. Xu Y, Iyengar S, Roberts RL, et al. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol 2003; 196: 131-43.
156. Laidler P, Dulinska J, Mrozicki S. Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines? Arch Biochem Biophys 2007; 462: 1-12.
157. Akinyeke TO, Stewart LV. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARgamma-independent mechanism. Cancer Biol Ther 2011; 11: 1046-58.
158. Lyles BE, Akinyeke TO, Moss PE, Stewart LV. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 2009; 8: 268-77.
159. Ban JO, Oh JH, Son SM, et al. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression. Cancer Biol Ther 2011; 12: 288-96.
160. Wei S, Lin LF, Yang CC, et al. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 2007; 72: 725-33.
161. Zhu H, Pan X, Qi H, et al. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells. Oncol Rep 2011; 25: 81-90.
162. Annicotte JS, Iankova I, Miard S, et al. Peroxisome proliferatoractivated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006; 26: 7561-74.
163. Hisatake JI, Ikezoe T, Carey M, et al. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000; 60: 5494-8.
164. Yang CC, Ku CY, Wei S, et al. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol Pharmacol 2006; 69: 1564-70.
165. Shiau CW, Yang CC, Kulp SK, et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of BclxL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005; 65: 1561-9.
166. Nunez NP, Liu H, Meadows GG. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 2006; 236: 133-41.
167. Papageorgiou E, Pitulis N, Manoussakis M, et al. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med 2008; 14: 403-11.
168. Sankpal UT, Goodison S, Abdelrahim M, Basha R. Targeting Sp1 transcription factors in prostate cancer therapy. Med Chem 2011; 7: 518-25.
169. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006; 6: 53.
170. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-52.
171. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000; 97: 10990-5.
172. Smith MR, Manola J, Kaufman DS, et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101: 1569-74.
173. Gottfried E, Rogenhofer S, Waibel H, et al. Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol 2011; 67: 117-26.
174. Radhakrishnan SK, Gartel AL. The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle 2005; 4: 582-4.
175. Nakata S, Yoshida T, Shiraishi T, et al. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol Cancer Ther 2006; 5: 1827-35.
176. Walter B, Rogenhofer S, Vogelhuber M, et al. Modular therapy approach in metastatic castration-refractory prostate cancer. World J Urol 2010; 28: 745-50.
177. Inaba M, Otani Y, Nishimura K, et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005; 54: 55-9.
178. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol 1996; 23: 241-50.
179. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997; 94: 4312-7.
180. Motomura W, Okumura T, Takahashi N, et al. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000; 60: 5558-64.
181. Tsujie M, Nakamori S, Okami J, et al. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Exp Cell Res 2003; 289: 143-51.
182. Sasaki T, Fujimoto Y, Tsuchida A, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer. Pathobiology 2001; 69: 258-65.
183. Galli A, Ceni E, Crabb DW, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 2004; 53: 1688-97.
184. Vitale G, Zappavigna S, Marra M, et al. The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Biotechnol Adv 2011.
185. Motomura W, Tanno S, Takahashi N, et al. Involvement of MEKERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem Biophys Res Commun 2005; 332: 89-94.
186. Tsujie M, Nakamori S, Okami J, et al. Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Int J Oncol 2003; 23: 325-31.
187. Toyota M, Miyazaki Y, Kitamura S, et al. Peroxisome proliferatoractivated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci 2002; 70: 1565-75.
188. Kawa S, Nikaido T, Unno H, et al. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 2002; 24: 1-7.
189. Hong J, Samudio I, Liu S, et al. Peroxisome proliferator-activated receptor gamma-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 2004; 145: 5774-85.
190. Kumei S, Motomura W, Yoshizaki T, et al. Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun 2009; 380: 614-9.
191. Farrow B, O'Connor KL, Hashimoto K, et al. Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. Surgery 2003; 134: 206-12.
192. Koga H, Selvendiran K, Sivakumar R, et al. PPARgamma potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol 2011.
193. Takeuchi Y, Takahashi M, Sakano K, et al. Suppression of Nnitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferatoractivated receptor gamma. Carcinogenesis 2007; 28: 1692-6.
194. Itami A, Watanabe G, Shimada Y, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer 2001; 94: 370-6.
195. Borbath I, Horsmans Y. The Role of PPARgamma in Hepatocellular Carcinoma. PPAR Res 2008; 2008: 209520.
196. Rumi MA, Sato H, Ishihara S, et al. Peroxisome proliferatoractivated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 2001; 84: 1640-7.
197. Koga H, Sakisaka S, Harada M, et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazoneinduced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001; 33: 1087-97.
198. Cheng J, Nakamura H, Imanishi H, et al. Peroxisome proliferatoractivated receptor gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2, and ciglitazone, induce growth inhibition and cell cycle arrest in hepatic oval cells. Biochem Biophys Res Commun 2004; 322: 458-64.
199. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-40.
200. Hazra S, Xiong S, Wang J, et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004; 279: 11392-401.
201. Toyoda M, Takagi H, Horiguchi N, et al. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002; 50: 563-7.
202. Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006; 43: 134-43.
203. Shim J, Kim BH, Kim YI, et al. The peroxisome proliferatoractivated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. Int J Oncol 2010; 36: 223-31.
204. Borbath I, Leclercq I, Moulin P, et al. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 2007; 43: 1755-63.
205. Guo YT, Leng XS, Li T, et al. Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats. World J Gastroenterol 2004; 10: 3419-23.
206. Hashimoto E, Tokushige K. Hepatocellular carcinoma in nonalcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res 2011.
207. Trappoliere M, Tuccillo C, Federico A, et al. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 2005; 9: 299-304.
208. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009; 32: 787-800.
209. Liu SH, Shen CC, Yi YC, et al. Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals. Br J Pharmacol 2010; 160: 1963-72.
210. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000; 83: 1394-400.
211. Bazargani A, Khoramrooz SS, Kamali-Sarvestani E, et al. Association between peroxisome proliferator-activated receptorgamma gene polymorphism (Pro12Ala) and Helicobacter pylori infection in gastric carcinogenesis. Scand J Gastroenterol 2010; 45: 1162-7.
212. Prasad KN, Saxena A, Ghoshal UC, et al. Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease. Ann Oncol 2008; 19: 1299-303.
213. Chen Q, Zhou J, Jiang C, Chen J. Reversal of P-glycoproteinmediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone. J Huazhong Univ Sci Technolog Med Sci 2010; 30: 326-31.
214. Wang C, Wang J, Bai P. Troglitazone induces apoptosis in gastric cancer cells through the NAG-1 pathway. Mol Med Report 2011; 4: 93-7.
215. Nagamine M, Okumura T, Tanno S, et al. PPAR gamma ligandinduced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci 2003; 94: 338-43.
216. Takeuchi S, Okumura T, Motomura W, et al. Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells. Jpn J Cancer Res 2002; 93: 774-82.
217. Leung WK, Bai AH, Chan VY, et al. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004; 53: 331-8.
218. Kitamura S, Miyazaki Y, Hiraoka S, et al. PPARgamma inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets. Biochem Biophys Res Commun 1999; 265: 453-6.
219. Chen BL, Yu J, Zeng ZR, et al. Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression. Oncol Rep 2008; 20: 1093-7.
220. He Q, Pang R, Song X, et al. Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In vitro via PPARgamma Dependent and Independent Mechanisms. PPAR Res 2008; 2008: 649808.
221. Lu J, Imamura K, Nomura S, et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005; 65: 4769-74.
222. Takahashi N, Okumura T, Motomura W, et al. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135-9.
223. Collet N, Theoleyre S, Rageul J, et al. PPARgamma is functionally expressed in clear cell renal cell carcinoma. Int J Oncol 2011; 38: 851-7.
224. Yang FG, Zhang ZW, Xin DQ, et al. Peroxisome proliferatoractivated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 2005; 26: 753-61.
225. Inoue K, Kawahito Y, Tsubouchi Y, et al. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001; 287: 727-32.
226. Rumi MA, Sato H, Ishihara S, et al. Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferatoractivated receptor-gamma ligands. J Lab Clin Med 2002; 140: 17-26.
227. Al-Taie OH, Graf T, Illert B, et al. Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo. J Gastroenterol 2009; 44: 919-29.
228. Fujii D, Yoshida K, Tanabe K, et al. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest. Anticancer Res 2004; 24: 1409-16.
229. Kobuke T, Tazuma S, Hyogo H, Chayama K. A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma. Dig Dis Sci 2006; 51: 1650-7.
230. Han C, Demetris AJ, Michalopoulos GK, et al. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Hepatology 2003; 38: 167-77.
231. Suzuki S, Mori J, Yamazaki M, et al. Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma. Intern Med 2007; 46: 1723-7.
232. Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 2005; 12: 291-303.
233. Antonelli A, Ferrari SM, Fallahi P, et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf) 2009; 70: 946-53.
234. Dobson ME, Diallo-Krou E, Grachtchouk V, et al. Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology 2011; 152: 4455-65.
235. Sertznig P, Seifert M, Tilgen W, Reichrath J. Activation of vitamin D receptor (VDR)-and peroxisome proliferator-activated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines. Dermatoendocrinol 2009; 1: 232-8.
236. Botton T, Puissant A, Bahadoran P, et al. In vitro and in vivo antimelanoma effects of ciglitazone. J Invest Dermatol 2009; 129: 1208-18.
237. Mossner R, Schulz U, Kruger U, et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 2002; 119: 576-82.
238. Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. Pediatrics 2006; 117: 803-13.
239. Papi A, Rocchi P, Ferreri AM, et al. Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol Rep 2009; 21: 1083-9.
240. Liu Y, Meng Y, Li H, et al. Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375. Med Oncol 2006; 23: 393-402.
241. Freudlsperger C, Thies A, Pfuller U, Schumacher U. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells. Anticancer Res 2007; 27: 207-13.
242. Placha W, Gil D, Dembinska-Kiec A, Laidler P. The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 2003; 13: 447-56.
243. Freudlsperger C, Dahl A, Hoffmann J, et al. Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells. Phytother Res 2010; 24: 1354-8.
244. Reichle A, Bross K, Vogt T, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004; 101: 2247-56.
245. Reichle A, Vogt T, Coras B, et al. Targeted combined antiinflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 2007; 17: 360-4.